Biotech, Diagnostics, Financing

Visterra gets series B financing from Merck

Posted on 03 October 2014

Tags: ,

Merck is investing $30 million in a Series B round of financing for Visterra.

The Series B financing round was co-led by new Visterra investors, Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek Life Science Ventures.

Existing investors Polaris Partners, Flagship Ventures, Omega Funds and Alexandria Venture Investments, and new investor Cycad Group, also participated in the upsized financing.

Proceeds from the round will be used to advance the development of multiple product candidates from the company’s pipeline of novel monoclonal antibodies that target infectious diseases, including VIS410 for seasonal and pandemic influenza and VIS513 for dengue fever, into the clinic.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Finding Biopharma and Collaboration Partners

Related reports:  Entire Current Partnering reports catalog

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Financing Scorecard in CP Insight – view top life science financing deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply